MedTrace Logo

Effect of Early High-dose Epoetin Alfa During Cardiac Arrest (Pilot Study)

NCT00719498 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-05-17

No results posted yet for this study

Summary

The purpose of this study is to test the possible neuroprotective effect of early high dose erythropoietin alpha after out of hospital cardiac arrest (OHCA).

Conditions

  • Resuscitation
  • Cardiopulmonary
  • Cardiac Arrest

Interventions

DRUG

Epo-alpha

Sponsors & Collaborators

  • Janssen Cilag S.A.S.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag S.A.S. Clinical Trial · Janssen Cilag S.A.S.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Completion
2004-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00719498 on ClinicalTrials.gov